Key result
GATA4 and Sp1 synergistically activate the ANF promoter through direct interaction during cardiac hypertrophy, whereas Sp3 exerts an antagonistic effect.
Answers are grounded in this paper and cite their sources.
Premature for clinical translation in hypertrophy; leaves open whether GATA4-Sp1 targeting alters progression in human disease.
Cardiac hypertrophy in response to multiple stimuli has important physiological and pathological significances. GATA4 serves as a nuclear integrator of several signalling pathways during cardiac hypertrophy. Sp1 and Sp3 are also reported to be involved in this process. However, the mechanism by which GATA4 acts as a mediator, integrating these ubiquitously expressed transcriptional factors, is poorly understood. We found that the expression of GATA4 and Sp1 was up-regulated in the myocardium of a pressure overload hypertrophy rat model, as well in phenylephrine-induced (PE-induced) hypertrophic growth of neonatal cardiomyocytes. GST pull-down assays demonstrated that GATA4 could interact with Sp1 in vitro. Therefore, we proposed that GATA4 cooperates with Sp1 in regulating ANF expression, as its reactivation is closely linked with hypertrophy. Further studies demonstrated that GATA4 could activate the ANF promoter synergistically with Sp1 through direct interaction. In contrast, Sp3 exhibited antagonistic function, and overexpression of Sp3 repressed the transcriptional synergy between Sp1 and GATA4. We also found that Sp1 alone could activate the ANF promoter in cardiomyocytes, whereas Sp3 exerted negative effects on ANF expression. Bioinformatics analysis revealed novel Sp-binding sites on the ANF promoter. The recruitment of GATA4 and Sp1 on the ANF promoter was enhanced during phenylephrine-mediated hypertrophy, whereas the recruitment of Sp3 was reduced. The phosphorylation of GATA4 by ERK1/2 kinase could enhance the affinity between GATA4 and Sp1. Thus, our findings revealed the critical interaction of GATA4 and Sp1 in modulating ANF expression, indicating their involvement in cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2010) studied Cardiac hypertrophy. Phenylephrine-induced hypertrophy and GATA4/Sp1 interaction was evaluated on ANF expression and promoter activation. GATA4 and Sp1 synergistically activate the ANF promoter through direct interaction during cardiac hypertrophy, whereas Sp3 exerts an antagonistic effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: